A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

NCT05912517 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemolytic Disease of the Fetus and Newborn

Interventions

DRUG: Nipocalimab
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC